Sugen Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 12 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 28.96%
- Profit Growth 96.45%
- Ebitda 149.17%
- Net Worth -0.58%
- Total Assets 8.17%
About Sugen Pharma
Sugen Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 January 2012 and has a history of 13 years. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ajaykumar Sheth and Birju Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2012PTC068756
-
Company No.
068756
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Jan 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Sugen Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajaykumar Sheth
|
Director | 25-Jan-2012 | Current |
|
Birju Shah
|
Director | 25-Jan-2012 | Current |
Financial Performance of Sugen Pharma.
Sugen Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 28.96% increase. The company also saw a substantial improvement in profitability, with a 96.45% increase in profit. The company's net worth dipped by a decrease of 0.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sugen Pharma?
In 2022, Sugen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aarsh Remedies Private LimitedAjaykumar Sheth is a mutual person
-
A Square Remedies Private LimitedAjaykumar Sheth and Birju Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sugen Pharma?
Sugen Pharma has a workforce of 10 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sugen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sugen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
